CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$13.75 USD
+0.25 (1.85%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $13.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRVO 13.75 +0.25(1.85%)
Will CRVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CRVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVO
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CRVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVO
CervoMed files for $250M mixed securities shelf
CervoMed files $250M mixed securities shelf
CervoMed Ends $20 Million Stock Sales Agreement with BTIG
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CervoMed to present on neflamapimod as DLB treatment at CTAD